SmithKline's Avandia EU Monotherapy Indication Anticipated After 2003
A monotherapy indication for SmithKline Beecham's antidiabetic Avandia is not expected in Europe before 2003, the company said at a launch briefing July 24.
You may also be interested in...
SmithKline Beecham's thiazolidinedione antidiabetic Avandia is in the final stages of EU approval following a positive recommendation by the Committee for Proprietary Medicinal Products March 16.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials